Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and its diagnosis relies heavily on specialized imaging rather than traditional tissue sampling. In most cases, doctors can confirm HCC without a biopsy by using contrast-enhanced CT or MRI scans that reveal a characteristic blood flow pattern unique to this cancer. The diagnostic process typically begins with routine surveillance in people already known to be at high risk, particularly those with cirrhosis or chronic hepatitis.
Who Gets Screened and How Often
HCC surveillance is recommended for all patients with cirrhosis, regardless of what caused it, as well as certain patients with chronic hepatitis B even without cirrhosis. The standard protocol is an abdominal ultrasound every six months. Some centers also draw blood to check alpha-fetoprotein (AFP), a protein that can rise when liver cancer is present, though ultrasound remains the primary screening tool.
This six-month interval was established because it significantly improves the chances of catching HCC at an early, treatable stage. When a surveillance ultrasound picks up a suspicious nodule 1 cm or larger, the next step is a dedicated contrast-enhanced CT or MRI scan to characterize it further.
How Imaging Confirms HCC Without a Biopsy
HCC has a distinctive way of pulling in blood supply that sets it apart from most other liver tumors. Normal liver tissue gets most of its blood from the portal vein, but HCC tumors feed almost exclusively from the hepatic artery. This difference creates a telltale two-phase pattern on contrast-enhanced imaging.
During the arterial phase of a CT or MRI scan, the tumor lights up brighter than the surrounding liver because it’s gorging on arterial blood. This is called arterial phase hyperenhancement. Then, in later phases of the scan, the tumor becomes darker than the background liver as contrast washes out of it while the surrounding tissue continues to absorb contrast through the portal vein. This “washout” pattern is the hallmark of HCC. On CT scans, about 20% of HCC tumors show washout in the portal venous phase, but more than 90% show it in the later equilibrium phase, which is why radiologists carefully evaluate multiple time points.
A third feature radiologists look for is an enhancing capsule, a bright rim around the tumor visible in later scan phases. When a tumor 2 cm or larger shows arterial hyperenhancement plus any one of these additional features (washout, capsule, or rapid growth of 50% or more in six months), it is classified as definite HCC. For smaller tumors between 1 and 2 cm, the criteria are stricter, requiring specific combinations of these features to reach the same level of certainty.
The LI-RADS Scoring System
Radiologists use a standardized system called LI-RADS (Liver Imaging Reporting and Data System) to categorize liver nodules on a scale from definitely benign to definitely cancerous. This removes guesswork and ensures consistent reporting across different hospitals and imaging centers.
- LR-1 (Definitely benign): Simple cysts or classic hemangiomas. No further workup needed.
- LR-2 (Probably benign): Small nodules without worrisome features. Roughly 13% turn out to be HCC. Patients return to regular surveillance.
- LR-3 (Intermediate): Nodules with some but not enough features to confirm or rule out HCC. About 38% are eventually diagnosed as HCC. Follow-up imaging in three to six months is typical.
- LR-4 (Probably HCC): Nodules with most hallmark features but not the exact combination needed for a definitive call. Around 74% prove to be HCC. A multidisciplinary team discussion and sometimes a biopsy follow.
- LR-5 (Definitely HCC): The diagnosis is confirmed on imaging alone. About 94% of these are HCC, and 97% are malignant overall. No biopsy is needed.
- LR-M (Malignant, not specific for HCC): The tumor looks cancerous but has features that suggest it could be a different type of liver cancer, such as intrahepatic cholangiocarcinoma. Biopsy is often needed to tell them apart.
When a Biopsy Is Still Necessary
Because imaging is so reliable in the setting of cirrhosis, most HCC diagnoses never require a needle biopsy. But there are important exceptions. If HCC develops in a liver without cirrhosis, international guidelines strongly recommend biopsy for confirmation, since the imaging criteria were validated primarily in cirrhotic livers.
Biopsy is also needed when imaging results are inconclusive, falling into the LR-3 or LR-4 categories without resolving on follow-up. It plays a role when doctors need to distinguish HCC from other cancers that can arise in the liver, particularly intrahepatic cholangiocarcinoma. On imaging, HCC characteristically shows washout and a capsule (seen in 55% to 78% of cases), while cholangiocarcinoma tends to show peripheral enhancement and progressive central filling, a distinctly different pattern. Still, no single imaging feature is exclusive to either cancer, which is why tissue sampling becomes necessary in ambiguous cases.
Additionally, patients who are being considered for systemic therapy or liver transplantation may need biopsy to provide tissue for molecular testing that guides treatment decisions.
The Role of Blood Tests
Alpha-fetoprotein is the most widely used blood marker for HCC, but it’s far from perfect on its own. Its accuracy depends heavily on the threshold used. At the traditional cutoff of 400 ng/mL, AFP is highly specific (99%), meaning a level that high almost certainly indicates HCC. But it’s not very sensitive: only about 32% of people with HCC actually reach that level. Lowering the threshold to 20-100 ng/mL catches more cases (61% sensitivity) but also produces more false positives, with specificity dropping to 86%.
Because of these limitations, AFP is used as a complement to imaging rather than a standalone diagnostic tool. A rising AFP level in someone with cirrhosis raises suspicion and may prompt earlier or more aggressive imaging, but a normal AFP does not rule out HCC.
Contrast-Enhanced Ultrasound as an Alternative
Contrast-enhanced ultrasound (CEUS) is gaining acceptance as a diagnostic option alongside CT and MRI. Multiple international societies, including European, Japanese, Italian, German, and British liver organizations, now recommend CEUS in their HCC diagnostic algorithms. The European Association for the Study of the Liver endorses it as a first-line option equal to CT and MRI.
In the United States, the approach is more cautious. The AASLD positions CEUS as a second-line tool, recommended when CT and MRI are inconclusive, unavailable, or contraindicated, or when biopsy isn’t feasible. CEUS has the advantage of being radiation-free and can be performed at the bedside, making it particularly useful for patients who can’t undergo CT or MRI.
What Happens After Diagnosis: Staging
Once HCC is confirmed, doctors determine how far it has progressed using the Barcelona Clinic Liver Cancer (BCLC) staging system. This system is unique among cancer staging frameworks because it factors in not just tumor size and spread but also how well the liver itself is functioning, which is critical since most HCC develops in already-damaged livers.
At the earliest stages (BCLC 0 and A), patients with a single small tumor and well-preserved liver function are typically candidates for surgery to remove the tumor or for liver transplantation. The key factor is whether clinically significant portal hypertension is present: patients without it are better candidates for surgical removal. Those with intermediate-stage disease (BCLC B), meaning multiple tumors but still good liver function, are generally treated with therapies delivered directly through the liver’s arteries, such as chemoembolization or radiation. Advanced-stage disease (BCLC C), where cancer has spread beyond the liver or into blood vessels, calls for systemic drug therapy.
The staging assessment happens through a combination of the diagnostic imaging already obtained, additional scans to check for spread outside the liver, blood tests measuring liver function, and an evaluation of overall physical fitness. All of these pieces together determine which treatment path offers the best outcome for each individual patient.